Bayer: Science For A Better Life - research

Research at Bayer HealthCare

Anticancer medicine

1/1

Pooling ideas: (left to right) Dr. Bernd Buchmann, Dr. Ulrich Klar and Dr. Wolfgang Schwede discuss synthesis strategies for new anticancer substances.

Bayer’s successful acquisition of Schering gave a tremendous boost to Bayer HealthCare’s re-search capabilities in the battle against cancer. The title story features reports on promising substances that are currently undergoing clinical testing, and takes a look at the new approaches being taken by the Bayer Schering Pharma Division. One hopeful candidate for cancer patients, for example, is the epothilone class of active substance, which in laboratory experiments cause tumor cells to burst.

Bayer’s cancer specialists are also targeting breast cancer and have developed a new anticancer substance as an alternative to the existing treatments. Finally, the essay by Professor Otmar Wiestler from the German Cancer Research Center (DKFZ) on tumor stem cells describes how cancer treatment could change in the future.